Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.

Jingpei Li,Jun Liu,Zhuo-Yi Li,Fei Cui,Yuan Zeng,Wenhua Liang,Hengrui Liang,Wei Wang,Ke Xu,Weipeng Cai,Jun-Hui Fu,Jianxing He

Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.

2021

Jingpei Li
Jun Liu
Zhuo-Yi Li
Fei Cui
Yuan Zeng
Wenhua Liang
Hengrui Liang
Wei Wang
Ke Xu
Weipeng Cai
Jun-Hui Fu
Jianxing He

4028Background: Despite multidisciplinary therapies, prognosis of pts with resectable esophageal squamous cell carcinoma (ESCC) remains poor. Combining PD-1 blockade to neoadjuvant chemotherapy mig...

Keywords:

locally advanced
esophageal squamous cell carcinoma
Oncology
Blockade
Chemotherapy
Medicine
open label
Internal medicine
Neoadjuvant therapy
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations